Carmelo Bengala - Concepedia

Author

Carmelo Bengala

University of Modena and Reggio Emilia

Also Known As

C Bengala, C. Bengala, Carmelo Bengala, Giacomo Allegrini, Michele Orditura, Paolo Pedrazzoli

Publications

Citations

H-Index

Concepts

All Affiliations

University of Modena and Reggio Emilia Azienda Ospedaliera Universitaria Pisana University of Pisa Fondazione IRCCS Istituto Nazionale dei Tumori Azienda Ospedaliero-Universitaria di Modena

About

Carmelo Bengala is an author at University of Modena and Reggio Emilia specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	812
2	Health Sciences	4	4	212
3	Blood Transplantation	1	1	13
4	Cell Biology	1	1	12
5	Marrow Transplantation	1	1	13

Carmelo Bengala

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, The Lancet Oncology OncologyMedicineColorectal CancerPathologyUpfront Folfoxiri	2020	309
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study Richard S. Finn, Carmelo Bengala, Nuhad K. Ibrahim, Clinical Cancer Research	2011	216
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial Carmelo Bengala, Federica Bertolini, N. Malavasi, British Journal of Cancer	2009	215
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial Denise A. Yardley, Rob Coleman, Pierfranco Conté, Annals of Oncology	2018	130
Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors Alessandra Gennari, B. Salvadori, Sara Donati, Journal of Clinical Oncology	1999	114
Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. Carlo Tondini, M. Zanini, Francesco Lombardi, Journal of Clinical Oncology	1993	111
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy Federica Bertolini, Carmelo Bengala, Luisa Losi, International Journal of Radiation OncologyBiologyPhysics Neoadjuvant ChemoradiotherapyGastrointestinal OncologyMedicineColorectal CancerPredictive Value	2007	106
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer Carmelo Bengala, Stefania Bettelli, Federica Bertolini, Annals of Oncology Radiation TherapyMedicinePathologyColorectal CancerK-ras Mutation	2008	89
Neoadjuvant Treatment With Single-Agent Cetuximab Followed by 5-FU, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer Federica Bertolini, Silvana Chiara, Carmelo Bengala, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineRadiation TherapyGastrointestinal OncologyMedicineNeoadjuvant Treatment	2008	83
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study* Pierfranco Conté, Alessandra Gennari, Sara Donati, Breast Cancer Research and Treatment Advanced Breast CancerBreast OncologyMedicinePharmacologyBreast Cancer	2001	72

Page 1